DeepMed Research

DAMANHOUR UNIVERSITY

🇪🇬Egypt

Country: 🇪🇬Egypt

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: -

Website: http://www.damanhour.edu.eg

Clinical Trials

Alpha-lipoic Acid in Diabetic Patients With Ischemic Cardiomyopathy

Not Applicable

Completed

Conditions: Diabetes Mellitus
Ischemic Cardiomyopathy

Interventions: Other: Placebo Tablet
Drug: Alpha Lipoic Acid 600 MG Oral Tablet

First Posted Date: 2023-09-28

Last Posted Date: 2024-02-21

Lead Sponsor: Damanhour University

Target Recruit Count: 60

Registration Number: NCT06056687

Locations: 🇪🇬
Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes., Damanhūr, Elbehairah, Egypt

Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.

Not Applicable

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sorafenib Tablets

First Posted Date: 2023-09-11

Last Posted Date: 2024-03-12

Lead Sponsor: Damanhour University

Target Recruit Count: 100

Registration Number: NCT06030895

Locations: 🇪🇬
Mansoura University Hospital, Mansoura, El-Dakahelia, Egypt

Effect of Montelukast on Doxorubicin Induced Cardiotoxicity in Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer
Doxorubicin Induced Cardiotoxicity

Interventions: Other: Placebo
Drug: Montelukast

First Posted Date: 2023-07-25

Last Posted Date: 2025-02-04

Lead Sponsor: Damanhour University

Target Recruit Count: 50

Registration Number: NCT05959889

Locations: 🇪🇬
Damanhour Oncology Center, Damanhūr, Elbehairah, Egypt

Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting

Completed

Conditions: Ciprofloxacin Adverse Reaction

Interventions: Drug: Ciprofloxacin Tablets

First Posted Date: 2023-06-23

Last Posted Date: 2023-06-23

Lead Sponsor: Damanhour University

Target Recruit Count: 151

Registration Number: NCT05916105

Locations: 🇪🇬
Rehab Hussein Werida, Damanhūr, Elbehairah, Egypt

Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

Completed

Conditions: Heart Failure
Stable Angina

Interventions: Other: Group I
Other: Group III
Other: Group II
Other: Group I Healthy
Drug: CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
Drug: HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study

First Posted Date: 2023-06-22

Last Posted Date: 2025-01-07

Lead Sponsor: Damanhour University

Target Recruit Count: 180

Registration Number: NCT05911724

Locations: 🇪🇬
Tanta University Hospital, Tanta, El-Gharbia, Egypt

Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients

Phase 2

Completed

Conditions: ST-segment Elevation Myocardial Infarction

Interventions: Drug: Atorvastatin 40mg
Drug: Rosuvastatin 20 mg

First Posted Date: 2023-06-08

Last Posted Date: 2024-08-01

Lead Sponsor: Damanhour University

Target Recruit Count: 80

Registration Number: NCT05895123

Locations: 🇪🇬
Damanhour University, Damanhūr, Egypt

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: Sacubitril / Valsartan Oral Tablet
Drug: Valsartan 80 mg

First Posted Date: 2023-05-31

Last Posted Date: 2023-06-27

Lead Sponsor: Damanhour University

Target Recruit Count: 80

Registration Number: NCT05881720

Locations: 🇪🇬
Tanta University Hospital, Tanta, Elgarbia, Egypt

Assessment of Safety and Satisfaction Toward COVID-19 Vaccines.

Completed

Conditions: COVID-19 Vaccine Adverse Reaction

First Posted Date: 2023-05-12

Last Posted Date: 2023-05-23

Lead Sponsor: Damanhour University

Target Recruit Count: 508

Registration Number: NCT05857176

Locations: 🇪🇬
Rehab Hussein Werida, Damanhūr, Elbehairah, Egypt

Valproic Acid Use in Patients With Neurological Disorders

Not Applicable

Completed

Conditions: Neurological Disorders

Interventions: Other: Educational intervention

First Posted Date: 2023-04-26

Last Posted Date: 2024-10-01

Lead Sponsor: Damanhour University

Target Recruit Count: 600

Registration Number: NCT05830981

Fenofibrate Role in Breast Cancer Patients

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Fenofibrate 160mg

First Posted Date: 2023-04-14

Last Posted Date: 2024-08-09

Lead Sponsor: Damanhour University

Target Recruit Count: 50

Registration Number: NCT05813145

Locations: 🇪🇬
Damanhour Oncology Center, Damanhūr, Elbehairah, Egypt

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy